If you want the shortest possible answer, it is this: Mounjaro usually wins the efficacy argument, but Ozempic still wins some very real situations. The problem is that most comparison pages flatten the decision into one fake question. They act like everyone wants the same thing, has the same insurance, and is using the same dose for the same diagnosis. That is not how this works.
Ozempic is the brand name for semaglutide used in type 2 diabetes. Mounjaro is the brand name for tirzepatide used in type 2 diabetes. They are both once-weekly injections, and Ozempic now also comes as a daily tablet. [18] They both commonly cause gastrointestinal side effects. They are not equally strong in the direct trial data we have. [1] [4] [5]
But here is the part that gets lost: if you are really asking about weight loss, then “Ozempic vs Mounjaro” is often the wrong comparison. The on-label obesity versions are Wegovy for semaglutide and Zepbound for tirzepatide. That matters because the obesity doses are higher, the trial populations are different, and the practical conversation with your prescriber changes. [4] [5] [6] [7]
If you want the molecule-level comparison first, read our full tirzepatide vs semaglutide breakdown. If you want the semaglutide brand map first, start with our semaglutide guide. This page is for the person trying to decide what to discuss at the next appointment.
What is the difference between Ozempic and Mounjaro?
Ozempic and Mounjaro are both approved for type 2 diabetes. Ozempic’s FDA label also includes cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease, and kidney risk reduction in adults with type 2 diabetes and chronic kidney disease. [4]
Mounjaro’s FDA label covers improving glycemic control in adults and children 10 and older with type 2 diabetes. Since August 2026, it also covers reducing the risk of major adverse cardiovascular events (cardiovascular death, heart attack, or stroke) in adults with type 2 diabetes who are at high risk for them. It does not include a kidney indication. [5]
For obesity treatment, the sister brands are:
| Molecule | Diabetes brand | Obesity brand |
|---|---|---|
| Semaglutide | Ozempic | Wegovy |
| Tirzepatide | Mounjaro | Zepbound |
That brand split is not just marketing. It affects the approved use, the target dose, the insurance logic, and the evidence you can honestly apply to your situation. [4] [5] [6] [7]
Quick comparison table: the honest version
If you want the fastest side-by-side, use this table with one important caveat: the A1C and nausea rows come from the direct SURPASS-2 diabetes trial, while the weight-loss rows use the obesity-dose sister-brand trials, because the randomized obesity-dose head-to-head, SURMOUNT-5, compared the drugs at Wegovy and Zepbound doses, not Ozempic and Mounjaro doses. [1] [2] [3] [14]
| Decision point | Ozempic / semaglutide side | Mounjaro / tirzepatide side |
|---|---|---|
| Injection frequency | Once weekly | Once weekly |
| HbA1c change in direct diabetes trial (SURPASS-2) | -1.86% with semaglutide 1 mg | -2.01%, -2.24%, and -2.30% with tirzepatide 5 mg, 10 mg, and 15 mg |
| Nausea incidence in direct diabetes trial (SURPASS-2) | 18% | 17% to 22% |
| Weight-loss signal in obesity-dose sister-brand trials | STEP 1 semaglutide 2.4 mg: -14.9% at 68 weeks | SURMOUNT-1 tirzepatide 5 mg, 10 mg, and 15 mg: -15.0%, -19.5%, and -20.9% at 72 weeks |
| Weight loss in the obesity-dose head-to-head (SURMOUNT-5, 72 weeks) | Semaglutide 1.7 or 2.4 mg: -13.7% | Tirzepatide 10 or 15 mg: -20.2% |
| Public pricing, as of October 25, 2026 | Pen self-pay $349/month for 0.25 mg to 1 mg and $499/month for 2 mg, with a $199 two-month intro offer for new 0.25 mg or 0.5 mg patients through December 31, 2026; Ozempic tablets $149 to $299/month | LillyDirect self-pay from $499/month; with coverage, the savings card can bring a 1- to 3-month fill to as little as $25; Lilly’s January 2025 disclosure sheet lists WAC at $1,079.77 per four-pen package |
That table is useful for orientation, but it still mixes direct diabetes data with indirect obesity-dose data. If you do not keep those frames separate, the comparison gets sloppy fast. [9] [10] [11] [14] [16] [17]
The actual head-to-head data: Mounjaro beat Ozempic in SURPASS-2
The direct comparison everybody cites is SURPASS-2, published in the New England Journal of Medicine in 2021. This trial compared tirzepatide 5 mg, 10 mg, and 15 mg against semaglutide 1 mg in adults with type 2 diabetes over 40 weeks. [1]
That detail matters: this was tirzepatide versus semaglutide 1 mg, not tirzepatide versus Wegovy’s 2.4 mg obesity dose.
Here is what the trial actually found:
| Trial result | Ozempic-level comparator: semaglutide 1 mg | Mounjaro: tirzepatide 5 mg | Mounjaro: tirzepatide 10 mg | Mounjaro: tirzepatide 15 mg |
|---|---|---|---|---|
| Mean A1C change at 40 weeks | -1.86% | -2.01% | -2.24% | -2.30% |
| Weight result versus semaglutide | baseline comparator | 1.9 kg more loss | 3.6 kg more loss | 5.5 kg more loss |
| Nausea | 18% | 17% | within 17% to 22% range | within 17% to 22% range |
| Diarrhea | 12% | within 13% to 16% range | within 13% to 16% range | within 13% to 16% range |
So if the question is strictly, “Which diabetes brand had the stronger direct efficacy data in type 2 diabetes?” the answer is Mounjaro. [1]
That said, the usual online jump from this result to “Mounjaro is always better” is too sloppy. A stronger average response does not erase differences in label, insurance, cardiovascular outcomes data, kidney data, or what you are actually trying to treat.
Which is better for weight loss: Ozempic or Mounjaro?
This is where a lot of people get misled.
If you do not have type 2 diabetes and you are mostly trying to treat obesity, then Ozempic versus Mounjaro is not the most clinically honest frame. Wegovy and Zepbound are.
In STEP 1, semaglutide 2.4 mg produced a mean body-weight change of -14.9% at 68 weeks versus -2.4% with placebo. In SURMOUNT-1, tirzepatide produced mean body-weight changes of -15.0%, -19.5%, and -20.9% at 72 weeks with the 5 mg, 10 mg, and 15 mg doses, versus -3.1% with placebo. [2] [3]
Those are separate trials in different populations, not a randomized head-to-head. But they explain why a weight-loss decision should usually be framed as Wegovy versus Zepbound, not Ozempic versus Mounjaro. Once semaglutide is pushed to the 2.4 mg obesity dose, the comparison you actually care about changes. [2] [3] [6] [7]
That obesity-dose comparison now has a direct trial. In SURMOUNT-5, adults with obesity but without diabetes lost 20.2% of their body weight on tirzepatide (10 or 15 mg) versus 13.7% on semaglutide (1.7 or 2.4 mg) over 72 weeks. The trial was open-label and funded by Lilly, which makes tirzepatide. [14]
For the practical version of that comparison, see our tirzepatide vs semaglutide article. For the full side-effect picture, keep our GLP-1 side effects guide open in the next tab.
Side effects: the real tradeoff is potency versus tolerability, not potency versus safety
Both drugs commonly cause nausea, vomiting, diarrhea, constipation, and stomach pain, especially during dose escalation. Ozempic’s current FDA label (revised May 2026) lists nausea, vomiting, diarrhea, abdominal pain, and constipation among the most common adverse reactions. Mounjaro’s current FDA label (revised August 2026) lists nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain among the most common side effects. [4] [5]
That is why the side-effect question should not be framed as “Which one has side effects?” They both do.
The more useful question is:
Can I tolerate the escalation path needed to get the result I want?
SURPASS-2 is helpful here because it shows the discomfort was not wildly asymmetric. Gastrointestinal events were the most common adverse events in both groups. Nausea ran 17% to 22% across tirzepatide doses versus 18% with semaglutide 1 mg, and vomiting ran 6% to 10% with tirzepatide versus 8% with semaglutide. [1]
That does not mean the day-to-day experience feels identical. It means the common internet framing of “Mounjaro works better and somehow also feels easier for most people” is not supported by the head-to-head data we have.
Dosing differences that matter in real life
Ozempic starts at 0.25 mg once weekly for 4 weeks, then increases to 0.5 mg, with possible escalation to 1 mg and 2 mg if additional glycemic control is needed. [4] Ozempic tablets start at 1.5 mg once daily for 30 days, then 4 mg, with an optional increase to 9 mg. [18]
Mounjaro starts at 2.5 mg once weekly. Under the label revised in August 2026, the dose goes up in 2.5 mg increments, after at least 4 weeks on the current dose, if more glycemic control is needed, to a maximum of 15 mg in adults (10 mg in children 10 and older). The earlier label required a step up to 5 mg after 4 weeks and said 2.5 mg was not meant for glucose control; the current label no longer says that. [5] Our dose titration guide walks through every step.
For obesity brands, the maintenance doses are different again:
- Wegovy: maintenance for weight reduction is 2.4 mg once weekly, with 1.7 mg as an alternative. The June 2026 label also lets adults go up to 7.2 mg once weekly after at least 4 weeks on 2.4 mg, if more weight loss is clinically indicated. [6]
- Zepbound: maintenance is 5 mg, 10 mg, or 15 mg once weekly for weight reduction and long-term maintenance (10 mg or 15 mg for sleep apnea). [7]
This matters because people often compare a diabetes dose on one side to an obesity dose on the other without realizing it. That is how bad comparison charts get made.
Which has heart and kidney benefits: Ozempic or Mounjaro?
As of October 2026, both drugs have heart-outcome labeling in type 2 diabetes, but they got there differently, and only Ozempic has a kidney indication.
- Ozempic: its current label includes cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease, and kidney risk reduction (sustained eGFR decline, end-stage kidney disease, and cardiovascular death) in adults with type 2 diabetes and chronic kidney disease. [4]
- Mounjaro: the August 2026 label added cardiovascular risk reduction in adults with type 2 diabetes at high risk. It rests on SURPASS-CVOT, in which 13,299 adults with type 2 diabetes and heart disease took tirzepatide or dulaglutide, a GLP-1 drug already shown to cut heart events. A heart attack, stroke, or cardiovascular death occurred in 12.2% versus 13.1% (hazard ratio 0.92). Tirzepatide met the test for non-inferiority but was not proven superior. [5] [15]
Semaglutide also has direct cardiovascular outcomes evidence in obesity without diabetes. In the SELECT trial, semaglutide 2.4 mg reduced major adverse cardiovascular events from 8.0% with placebo to 6.5%, a hazard ratio of 0.80, in adults with preexisting cardiovascular disease and overweight or obesity but without diabetes. [8]
That does not mean Ozempic automatically beats Mounjaro for every patient with heart risk. It means there are situations where the smarter question is not “Which one loses more weight on average?” but “Which one has the outcomes data and label language that match my problem?”
How much do Ozempic and Mounjaro cost in 2026?
The best drug on paper is often the wrong drug in your formulary. As of October 25, 2026, here is the practical cost picture from the official patient-facing sources we could verify:
| Cost question | Ozempic | Mounjaro |
|---|---|---|
| Commercial coverage offer | Ozempic’s savings offer says commercially insured patients may pay as little as $25 per month, with maximum savings of $100 per month. [9] [16] | Mounjaro’s savings card says eligible patients with coverage may pay as little as $25 for a 1-, 2-, or 3-month fill, with maximum savings of $150 per month. Without Mounjaro coverage, the card price is as low as $499 per month. [10] |
| Self-pay or cash-style public offer | NovoCare lists self-pay pricing of $349/month for the Ozempic 0.25 mg, 0.5 mg, or 1 mg pen and $499/month for 2 mg, with a limited-time $199/month offer for the first two months for new 0.25 mg and 0.5 mg patients through December 31, 2026. Ozempic tablets are $149 to $299/month depending on dose. [9] [16] | LillyDirect lists Mounjaro self-pay at $499/month for every dose. [17] Lilly’s Connecticut disclosure sheet, dated January 2025, lists the wholesale acquisition cost at $1,079.77 per four-pen package. [11] |
Two important honesty notes:
- List price is not the same thing as out-of-pocket price. Pharmacy markups, deductibles, copay accumulators, and plan rules can make the cheaper-looking drug more expensive for you.
- If your actual goal is obesity treatment, the patient offers are often better discussed on the Wegovy and Zepbound pages, not the diabetes-brand pages. As of October 25, 2026, NovoCare’s Wegovy page says commercially insured patients may pay as little as $25/month, and self-pay is $349/month for the pen ($199 for the first two months for new 0.25 mg or 0.5 mg patients through December 31, 2026) or $399/month for the 7.2 mg Wegovy HD pen. Lilly’s Zepbound page lists self-pay at $299 to $449/month when refills are on time, and as little as $25 with coverage. [12] [13]
If cost is the main issue, jump to our telehealth and access comparison after this, or run your situation through the GLP-1 Price Check tool.
Which one fits your situation?
Use this as a decision tree, not as medical advice.
If your main goal is strongest A1C reduction in type 2 diabetes
Start with Mounjaro on the discussion list.
Why: the best direct head-to-head diabetes data we have favors tirzepatide over semaglutide 1 mg for both A1C and weight. [1]
If your main goal is obesity treatment and you do not have type 2 diabetes
Do not stop at the Ozempic-versus-Mounjaro framing.
Ask instead about Wegovy versus Zepbound, because those are the obesity brands and doses. [6] [7]
If you have type 2 diabetes plus established cardiovascular disease or chronic kidney disease
Both deserve a serious look, for different reasons.
Why: as of August 2026, both labels include cardiovascular risk reduction in type 2 diabetes, but only Ozempic’s label includes kidney risk reduction in adults with type 2 diabetes and chronic kidney disease. [4] [5]
If you know nausea is the thing that knocks you out
Do not assume Ozempic is the “gentler” pick or Mounjaro is the “stronger but easier” pick.
Why: the GI burden is substantial with both, and the head-to-head nausea numbers are in the same neighborhood. [1]
If your insurance only clearly covers one
That may be the real answer.
The percentage-point debate matters less if one option is affordable and the other becomes a four-figure monthly problem.
The bottom line
For a person with type 2 diabetes deciding between the two diabetes brands, Mounjaro has the stronger direct efficacy data. That is the cleanest evidence-based takeaway.
But “stronger on average” is not the same thing as “better for everyone.” Ozempic can still be the smarter fit when kidney label language matters, when a daily tablet would help, when your insurer prefers it, or when your prescriber wants semaglutide’s evidence base for your specific situation.
And if your real question is weight loss, be blunt about that. The comparison should usually shift to Wegovy versus Zepbound, because that is the version of the question that actually matches the treatment goal.
If you want more research-first GLP-1 explainers with the numbers left in, join the newsletter. That is where we send the trial updates, coverage changes, and comparison tables worth saving.
